Dr Arnab Datta qualified from Jesus College, Cambridge with a first class degree in Neurophysiology, before completing his medical training at University College, London (UCL), graduating with a Distinction and several University prizes.

He trained at several of the country's top teaching hospitals, including The Royal Brompton Hospital and St Mary's Hospital, before being award a prestigious Wellcome Trust Fellowship (2008) and completing his PhD in Interstitial Lung Disease at UCL (2011), resulting in the publication of several high impact research articles.

He was recently appointed as Care Group Clinical Director of Integrated Cancer Services for London North West University Hospitals NHS Trust (LNWUH) covering oncology, cancer performance, palliative care, haematology and dermatology, and is responsible for overall cancer performance across all tumour sites for LNWUH as well as leading on the strategic development of cancer services for the trust. Under his leadership, LNWUH ranked 10th nationally in terms of key cancer performance metrics, including time to diagnosis and treatment (25/26).

He is additionally the Lung Cancer Lead at LNWUH, managing the delivery of lung cancer services across Brent, Harrow and Ealing. Through case by case assessment of all referrals, and weekly coordination of care with oncologists and thoracic surgeons, he has increased the capacity of the Trust to see all patients within national targets, improving time to diagnosis and treatment. As a direct result of these initiatives, LNWUH lung cancer service consistently ranks 1st/2nd across NW and SW London in terms of time to diagnosis and treatment.

Dr Datta was appointed as a Consultant in Respiratory Medicine at LNWUH in 2012, as well as an Honorary Consultant at Imperial College Healthcare NHS Trust (ICHT) in Interstitial Lung Disease (ILD). Building on his research, he set up the ILD service at LNWUH collaborating with ICHT to ensure patients could be fast-tracked for specially commissioned drugs and interventions, as well facilitating recruitment into trials. He has published in peer-reviewed journals and has an on-going interest in clinical research with partners at ICHT. Recent work has focused on developing novel Patient Reported Experience Measures for patients with lung fibrosis, and hub and spoke pathways facilitating early diagnosis and treatment.

As well as being a highly skilled bronchoscopist, he developed and expanded the Endobronchial Ultrasound (EBUS) service at LNWUH which has further significantly reduced the waiting time to treatment of patients with lung cancer, tuberculosis and other significant lung diseases such as sarcoid. He oversees the running of 2 lists / week, and performs ~250 EBUS cases / year
He is additionally involved in managing the High Dependency Unit, directing the care of severely ill patients including those with respiratory failure and his expertise in interstitial lung disease has proved critical in managing the sequelae of COVID pneumonia such as lung fibrosis.

Dr Datta's clinical practice involves managing patients across the entire range of respiratory symptoms and conditions. He is consulted about cough, breathlessness and wheeze, as well as sputum production, coughing up blood (haemoptysis) and chest pain. He treats patients with chronic cough, asthma, COPD and lung cancer, as well as pleural conditions, including pleural effusions and pneumothoraces. His specialist interest is the management of patients with fibrotic lung disease, including idiopathic pulmonary fibrosis and sarcoid, as well as lung cancer.

Clinical Interests

• Lung cancer
• Interstitial Lung Disease
• COPD
• Asthma
• Pleural disease
• Bronchiectasis
• Endobronchial ultrasound and bronchoscopy

• British Thoracic Society
• European Respiratory Society
• American Thoracic Society